Legalize It, Don’t Criticize It

SEATTLE (AP) — President Donald Trump’s decision to reclassify state-licensed medical marijuana as a less dangerous drug is a boon for the industry: It gives dispensaries a big tax break, eases some barriers to researching cannabis and could even allow the export of marijuana to other countries.

But that might only be Trump’s first step. A new administrative hearing slated for the end of June could result in the reclassification of marijuana more broadly, granting tax and other benefits to state-licensed recreational markets, too.

“This is a signal that this administration means business on getting this done,” said Boston-based cannabis industry attorney Jesse Alderman, of the firm Foley Hoag.

The order issued Thursday does not legalize marijuana for medical or recreational use under federal law, and it is likely to face legal challenges.

But it does change the way marijuana is regulated, shifting licensed medical marijuana from Schedule I — reserved for drugs without medical use and with high potential for abuse — to the less strictly regulated Schedule III.

It was a significant policy shift for a U.S. government that has been steadfast in its prohibition of pot, even as all states but two — Idaho and Kansas — have approved cannabis in some form since California became the first to OK the medical use of marijuana in 1996.

Two dozen states plus Washington, D.C., have authorized adult recreational use of marijuana, raising billions in tax revenue. Forty have medical marijuana systems, and eight others allow low-THC cannabis or CBD oil for medical use.

The order noted that regulation of medical marijuana has come a long way, with comprehensive licensing polices from cultivation to sales in most states.

About the Author

Wayne Creed

Administrator

View All Posts